| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/02/2013 | CN101534861B Polyalkylene oxides having hindered ester-based biodegradable linkers |
| 10/02/2013 | CN101528256B Use of anti-CD151 antibody in treatment of cancer |
| 10/02/2013 | CN101437539B Blocking leukocyte emigration and inflammation by interfering with CD99l2 |
| 10/01/2013 | US8546542 Anti-sweat antigen monoclonal antibody |
| 10/01/2013 | US8546538 B lymphocyte chemoattractant (CXCL13) specific immunoglobulin for use in treatment and prevention of autoimmune encephalomyelitis |
| 10/01/2013 | US8546337 Self-assembling peptide nanoparticles useful as vaccines |
| 10/01/2013 | US8546331 Modulation of pathogenic CD14+/CD16+ monocytes |
| 10/01/2013 | US8546124 Generating preferential vector nucleotide sequences, obtaining nucleotide sequences, incubating with preferential exogenous nucleotide sequences, ligating, recovering nucleotide sequences |
| 10/01/2013 | US8546123 Production of poliovirus at high titers for vaccine production |
| 10/01/2013 | US8545854 Tuberculosis vaccine with improved efficacy |
| 10/01/2013 | US8545853 Recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| 10/01/2013 | US8545852 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines |
| 10/01/2013 | US8545851 Composition for improving inflammatory disease using ABH antigens |
| 10/01/2013 | US8545850 Anti-CD79B antibodies and immunoconjugates and methods of use |
| 10/01/2013 | US8545849 Stable and soluble antibodies |
| 10/01/2013 | US8545848 Human cytomegalovirus neutralising antibodies and use thereof |
| 10/01/2013 | US8545847 Human antibodies to the human glucagon receptor and methods of use thereof |
| 10/01/2013 | US8545846 Methods for treating IL-1β related diseases by administering an anti-IL-1β antibody |
| 10/01/2013 | US8545845 Antibodies against domains of laminin-332 |
| 10/01/2013 | US8545844 Humanized antibodies against human IL-22RA |
| 10/01/2013 | US8545843 Treatment of vasculitis |
| 10/01/2013 | US8545841 Methods and compositions for the treatment of cancers and pathogenic infections |
| 10/01/2013 | US8545840 Methods for treating cancer using an immunotoxin |
| 10/01/2013 | US8545839 Anti-c-Met antibody |
| 10/01/2013 | US8545838 Compositions and methods for cancer immunotherapy |
| 10/01/2013 | US8545835 Human prostate cell lines in cancer treatment |
| 10/01/2013 | US8545814 Non-invasive localization of a light-emitting conjugate in a mammal |
| 10/01/2013 | US8545812 Transport agents for crossing the blood-brain barrier and into brain cancer cells and methods of use thereof |
| 10/01/2013 | CA2725329C Nanoemulsion vaccines |
| 10/01/2013 | CA2689741C Latent human tuberculosis model, diagnostic antigens, and methods of use |
| 10/01/2013 | CA2582668C Nanoparticles comprising antigens and adjuvants, and immunogenic structures |
| 10/01/2013 | CA2563516C Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent |
| 10/01/2013 | CA2551008C Anti-cd40 antibody mutants |
| 10/01/2013 | CA2514510C Polymer conjugates of mutated neublastin |
| 10/01/2013 | CA2495456C Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof |
| 10/01/2013 | CA2481515C Anti-her2 antibody variants |
| 10/01/2013 | CA2479835C An ephrin-b receptor protein involved in carcinoma |
| 10/01/2013 | CA2436530C Environmentally regulated genes of streptococcus suis |
| 10/01/2013 | CA2433862C Molecular antigen array presenting amyloid beta |
| 10/01/2013 | CA2424379C Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| 10/01/2013 | CA2366520C Anti-bacterial vaccine compositions |
| 10/01/2013 | CA2353802C New protective antigen of group a streptococci |
| 10/01/2013 | CA2239448C Blockade of t lymphocyte down-regulation associated with ctla-4 signaling |
| 09/26/2013 | WO2013142875A1 Treatment of brain cancer |
| 09/26/2013 | WO2013142809A1 Baculovirus-based enterovirus 71 vlp as a vaccine |
| 09/26/2013 | WO2013142796A2 Methods of treatments using ctla4 antibodies |
| 09/26/2013 | WO2013142755A1 Method of treatment of wrinkles using topical chemodenervating agents |
| 09/26/2013 | WO2013142449A2 Treatment for chronic pain syndromes |
| 09/26/2013 | WO2013142377A2 Modified marek's disease virus, and vaccines made therefrom |
| 09/26/2013 | WO2013142371A1 Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof |
| 09/26/2013 | WO2013142349A1 Compositions and methods related to staphylococcal sbi |
| 09/26/2013 | WO2013142329A1 Virus -like particles comprising a matrix protein from a plant enveloped virus and uses thereof |
| 09/26/2013 | WO2013142324A1 Neutralizing antibodies to hiv-1 and their use |
| 09/26/2013 | WO2013142300A2 Jcv neutralizing antibodies |
| 09/26/2013 | WO2013142298A1 Stable peptide mimetics of the hiv-1 gp41 pre-hairpin intermediate |
| 09/26/2013 | WO2013142278A1 Plasmodium vivax vaccine compositions |
| 09/26/2013 | WO2013142245A1 Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition |
| 09/26/2013 | WO2013142182A2 Combination therapy |
| 09/26/2013 | WO2013142114A1 Growth differentiation factor (gdf) for treatment of diastolic heart failure |
| 09/26/2013 | WO2013141823A1 Modified bordetella pertussis strains |
| 09/26/2013 | WO2013140919A1 Lps vaccine |
| 09/26/2013 | WO2013140787A1 Preventive or therapeutic agent for idiopathic inflammatory myopathy |
| 09/26/2013 | WO2013140643A1 Carrier for intracellular delivery of functional protein |
| 09/26/2013 | WO2013140247A1 Antibodies that neutralize rsv, mpv and pvm and uses thereof |
| 09/26/2013 | WO2013140169A1 Immunogenic composition and methods of use thereof |
| 09/26/2013 | WO2013140136A1 Adjuvants |
| 09/26/2013 | WO2013139956A1 Antibodies abrogating cell binding to lactadherin |
| 09/26/2013 | WO2013139916A1 Vaccine against rsv |
| 09/26/2013 | WO2013139911A1 Vaccine against rsv |
| 09/26/2013 | WO2013139803A1 Carbohydrate-glycolipid conjugate vaccines |
| 09/26/2013 | WO2013139789A1 B-cell receptor complex binding proteins containing t-cell epitopes |
| 09/26/2013 | WO2013139744A1 Method of vaccination against human papillomavirus |
| 09/26/2013 | WO2013139655A1 Influenza vaccines |
| 09/26/2013 | WO2013139423A1 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds |
| 09/26/2013 | WO2013139393A1 Formulations for non-invasive delivery of active proteins to an animal or human |
| 09/26/2013 | WO2013139340A1 Hcv full-length genotype 2b consensus clone |
| 09/26/2013 | WO2013138871A1 Immunomodulatory agent and uses therefor |
| 09/26/2013 | WO2013090635A3 Composition and method for the diagnosis and treatment of iron-related disorders |
| 09/26/2013 | WO2013052174A3 Methods for preventing and treating staphylococcus aureus colonization, infection, and disease |
| 09/26/2013 | WO2012031273A9 Novel modulators and methods of use |
| 09/26/2013 | US20130253382 Targeted enzymatic degradation of quorum-sensing peptides |
| 09/26/2013 | US20130252889 Composition comprising vlp and amyloid beta peptide |
| 09/26/2013 | US20130252325 Duplexed Parvovirus Vectors |
| 09/26/2013 | US20130251752 Chemokine gene-modified cells for cancer immunotherapy |
| 09/26/2013 | US20130251750 Purified Plasmodium and Vaccine Composition |
| 09/26/2013 | US20130251749 Methods and compositions for chlamydial antigens as reagents/strategies for diagnosis and treatment of chlamydial infection and disease |
| 09/26/2013 | US20130251748 Use of outer membrane porin k36 protein (ompk36) in treatment/prevention/diagnosis of enterobacteriaceae infection |
| 09/26/2013 | US20130251747 Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof |
| 09/26/2013 | US20130251745 Vaccine |
| 09/26/2013 | US20130251742 COMPOSITION FOR TREATING PROSTATE CANCER (PCa) |
| 09/26/2013 | US20130251741 Immunostimulatory and vaccine compositions |
| 09/26/2013 | US20130251739 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines |
| 09/26/2013 | US20130251737 Modified Mareks Disease Virus, and Vaccines Made Therefrom |
| 09/26/2013 | US20130251734 Use of tam receptor inhibitors as antimicrobials |
| 09/26/2013 | US20130251733 Anti-cxcr3 antibodies |
| 09/26/2013 | US20130251732 Targeting of cyp1b1 in the treatment of head and neck cancer and lung cancer |
| 09/26/2013 | US20130251728 Method of Treating Stress Hyperglycemia with Human Antibodies to the Glucagon Receptor |
| 09/26/2013 | US20130251726 Novel hiv -1 broadly neutralizing antibodies |
| 09/26/2013 | US20130251725 Anti-P-Selectin Antibody Formulation |
| 09/26/2013 | US20130251711 Nk cell modulating treatments and methods for treatment of hematological malignancies |